Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 18, 2024$6.88
P/E Ratio
N/A
Market Cap
$488.97M
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Overview
Trading Information
Company